Samsung Biologics Co Ltd
KRX:207940
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
680 000
915 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Samsung Biologics Co Ltd
Intrinsic Value
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. [ Read More ]
The intrinsic value of one
Samsung Biologics Co Ltd
stock under the Base Case scenario is
380 906.39
KRW.
Compared to the current market price of 915 000 KRW,
Samsung Biologics Co Ltd
is
Overvalued by 58%.
Samsung Biologics Co Ltd's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
Samsung Biologics Co Ltd or that its price is influenced by factors unrelated to fundamentals.
Samsung Biologics Co Ltd's market capitalization is 65.1T KRW.
Samsung Biologics Co Ltd stock price is 915 000 KRW.
Samsung Biologics Co Ltd stock (380 906.39 KRW) is 58% less than its price (915000 KRW).
Samsung Biologics Co Ltd stock (167 604.27 KRW) is 82% less than its price (915000 KRW). Open DCF Valuation
Samsung Biologics Co Ltd stock (594 208.51 KRW) is 35% less than its price (915000 KRW). Open Relative Valuation
Samsung Biologics Co Ltd has upside potential of 15% compared to the average analyst price target.
Open Wall St Estimates
Samsung Biologics Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 9%.
Samsung Biologics Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 6% to 6%.
Samsung Biologics Co Ltd's ROE (Return on Equity) has increased in the last 3 years from 7% to 9%.
Samsung Biologics Co Ltd has positive three-year average ROE (Return on Equity): 9%. The company is efficient at transforming stockholders' equity into net income.
Samsung Biologics Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 6%.
Samsung Biologics Co Ltd's short-term assets (6T KRW) exceed its short-term liabilties (5T KRW).
Samsung Biologics Co Ltd has positive Free Cash Flow for the last twelve months.
Samsung Biologics Co Ltd's Revenue has grown by an exceptional 22% over the past 12 months.
Samsung Biologics Co Ltd has positive three-year average ROIC (Return on Invested Capital): 6%. The company is efficient at using invested capital to generate operating income.
Samsung Biologics Co Ltd's Revenue is forecast to grow at a rate of 15% per year over the next 3 years.
Samsung Biologics Co Ltd has positive Net Income for the last twelve months.
Samsung Biologics Co Ltd has positive Operating Income for the last twelve months.
Samsung Biologics Co Ltd has positive Gross Profit for the last twelve months.
Samsung Biologics Co Ltd's long-term assets (17T KRW) exceed its long-term liabilties (7T KRW).
Samsung Biologics Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (2T KRW) than debt (840B KRW).
Samsung Biologics Co Ltd's Revenue has been growing by an exceptional 48% per year for the last 3 years.
Samsung Biologics Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.08.
Samsung Biologics Co Ltd earns more than enough operating income (1T KRW) to safely cover interest payments on its debt (64B KRW).
Samsung Biologics Co Ltd's Altman Z-Score is very high and is equal to 6.23.
Valuation Backtest
Samsung Biologics Co Ltd
Run backtest to discover the historical profit from buying and selling
Samsung Biologics Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Samsung Biologics Co Ltd
| Current Assets | 5.6T |
| Cash & Short-Term Investments | 2T |
| Receivables | 760.4B |
| Other Current Assets | 2.8T |
| Non-Current Assets | 10.9T |
| Long-Term Investments | 42.3B |
| PP&E | 4.8T |
| Intangibles | 5.8T |
| Other Non-Current Assets | 295.6B |
| Current Liabilities | 4.6T |
| Accounts Payable | 187.3B |
| Accrued Liabilities | 227.3B |
| Short-Term Debt | 572B |
| Other Current Liabilities | 3.7T |
| Non-Current Liabilities | 1.9T |
| Long-Term Debt | 267.7B |
| Other Non-Current Liabilities | 1.6T |
Earnings Waterfall
Samsung Biologics Co Ltd
|
Revenue
|
3.9T
KRW
|
|
Cost of Revenue
|
-2T
KRW
|
|
Gross Profit
|
1.9T
KRW
|
|
Operating Expenses
|
-737.1B
KRW
|
|
Operating Income
|
1.1T
KRW
|
|
Other Expenses
|
-247.9B
KRW
|
|
Net Income
|
895.3B
KRW
|
Free Cash Flow Analysis
Samsung Biologics Co Ltd
| KRW | |
| Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
Samsung Biologics Co Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Samsung Biologics Co Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Samsung Biologics Co Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Samsung Biologics Co Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Samsung Biologics Co Ltd
According to Wall Street analysts, the average 1-year price target for
Samsung Biologics Co Ltd
is 1 050 988.57 KRW
with a low forecast of 787 800 KRW and a high forecast of 1 312 500 KRW.
Click here to dive deeper.
Price Appreciation
Price
Samsung Biologics Co Ltd
| Average Annual Return | 38.02% |
| Standard Deviation of Annual Returns | 46.07% |
| Max Drawdown | -32% |
| Market Capitalization | 65.1T KRW |
| Shares Outstanding | 71 174 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Samsung Biologics Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company is headquartered in Incheon, Incheon. The company went IPO on 2016-11-10. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. The company also provides cell line development and process development services. The firm distributes its products in domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Samsung Biologics Co Ltd
stock under the Base Case scenario is
380 906.39
KRW.
Compared to the current market price of 915 000 KRW,
Samsung Biologics Co Ltd
is
Overvalued by 58%.
You don't have any saved screeners yet
